Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue

Histopathology

Volumn 51, Issue 1, 2007, Pages 54-62

  Lindemann, K ^a,c   Resau, J ^d   Nahrig J ^a   Kort, E ^d   Leeser, B ^d   Annecke, K ^a   Welk, A ^a   Schafer J ^b   Vande Woude, G F ^d   Lengyel, E ^e   Harbeck, N ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^d VAN ANDEL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

c Met; DCIS; HER2 neu; HGF SF

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CONTROLLED STUDY; CORRELATION ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE GROWTH FACTOR; HUMANS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, ERBB-2;

EID: 34250804017     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02732.x     Document Type: Article

References (44)

1. Prat M, Narsimhan RP, Crepaldi T, Nicotra MR, Natali PG, Comoglio PM. The receptor encoded by the human c-Met oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int. J. Cancer 1991 49 323 328.
2. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003 4 915 925.
3. Weidner KM, Sachs M, Birchmeier W. The met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J. Cell. Biol. 1993 121 145 154.
4. Yamashita J, Ogawa M, Yamashita S et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res. 1994 54 1630 1633.
5. Tsarfaty I, Resau JH, Rulong S, Keydar I, Faletto DL, Vande Woude GF. The met proto-oncogene receptor and lumen formation. Science 1992 257 1258 1261.
6. Montesano R, Matsumoto K, Nakamura T, Orci L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 1991 67 901 908.
7. Soriano JV, Pepper MS, Nakamura T, Orci L, Montesano R. Hepatocyte growth factor stimultates extensive development of branching duct-like structures by cloned mammary gland epithelial cells. J. Cell. Sci. 1995 108 413 430.
8. Lengyel E, Prechtel D, Resau JH et al. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int. J. Cancer 2005 113 678 682.
9. Jeffers M, Rong S, Vande Woude GF. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J. Mol. Med. 1996 74 505 513.
10. Comoglio PM, Trusolino L. Series introduction: invasive growth: from development to metastasis. J. Clin. Invest. 2002 109 857 862.
11. Kang JY, Dolled-Filhart M, Ocal IT et al. Tissue microarray analysis of hepatocyte growth factor/met pathway components reveals a role for met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res. 2003 63 1101 1105.
12. Ghoussoub RA, Dillon DA, D'Aquila T, Rimm EB, Fearon ER, Rimm DL. Expression of c-met is a strong independent prognostic factor in breast caracinoma. Cancer 1998 82 1513 1520.
13. Camp RL, Rimm EB, Rimm DL. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 1999 86 2259 2265.
14. Ocal ID, Dolled-Filhart M, D'Aquila TG, Camp RL, Rimm DL. Tissue microarray based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but it is not correlated with epidermal growth factor family receptors. Cancer 2003 97 1841 1848.
15. Tsarfaty I, Rong S, Resau JH, Rulong S, da Silva PP, Vande Woude GF. The met proto-oncogene mesenchymal to epithelial cell conversion. Science 1994 263 98 101.
16. Tsarfaty I, Alvord WG, Resau JH et al. Alteration of met protooncogene expression and prognosis in breast carcinomas. Anal. Quant. Cytol. Histol. 1999 21 397 408.
17. Altstock RT, Stein GY, Resau JH, Tsarfaty I. Algorithms for quantification of protein expression variation in normal versus tumor tissue as a prognostic factor in cancer: met oncogene expression, and breast cancer as a model. Cytometry 2000 41 155 165.
18. Jin L, Fuchs A, Schnitt SJ et al. Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer 1997 79 749 760.
19. Borg A, Tandon AK, Sigurdsson H et al. Her-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990 50 4332 4337.
20. Ferrero-Pous M, Hacene K, Bouchet C, Le Doussal V, Tubiana-Hulin M, Spyratos F. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin. Cancer Res. 2000 6 4745 4754.
21. Menard S, Fortis S, Castiglioni F, Agresti R, Balsari A. HER2 as a prognostic factor in breast cancer. Oncology 2001 61 67 72.
22. Hoque A, Sneige N, Sahin AA et al. Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol. Biomarkers Prev. 2002 11 587 590.
23. Latta EK, Tjan S, Parkes RK, O'Malley FP. The role of Her2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod. Pathol. 2002 15 1318 1325.
24. Silverstein MJ, Lagios MD, Craig PH et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996 77 2267 2274.
25. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987 8 138 140.
26. Gusterson BA, Machin LG, Gullick WJ et al. c-erbB-2 expression in benign and malignant breast disease. Br. J. Cancer 1988 58 453 457.
27. van de Vijer MJ, Peterse JL, Mooi WJ et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N. Engl. J. Med. 1988 319 1239 1245.
28. Allred DC, Clark GM, Tandon AK et al. Her-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J. Clin. Oncol. 1992 10 599 605.
29. Di Fiore PP, Pierce JH, Fleming TP et al. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 1987 51 1063 1070.
30. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl Acad. Sci. USA 1987 84 7159 7163.
31. Slamon DJ, Godolphin W, Jones LA et al. Studies of Her-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989 244 707 712.
32. Rosen EM, Goldberg ID, Liu D et al. Tumor necrosis factor stimulates epithelial tumor cell motility. Cancer Res. 1991 51 5315 5321.
33. Bhargava M, Joseph A, Knesel J et al. Scatter factor and hepatocyte growth factor: activities, properties, and mechanism. Cell Growth Differ. 1992 3 11 20.
34. Rong S, Segal S, Anver M, Resau JH, Vande Woude GF. Invasiveness and metastasis if NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc. Natl Acad. Sci. USA 1994 91 4731 4735.
35. Jeffers M, Rong S, Vande Woude GF. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-Met signaling in human cells concomitant with induction of the urokinase proteolysis network. Mol. Cell. Biol. 1996 16 1115 1125.
36. Beviglia L, Matsumoto K, Lin CS, Ziober BL, Kramer RH. Expression of the c-Met/HGF receptor in human breast carcinoma: Correlation with tumor progression. Int. J. Cancer 1997 74 301 309.
37. Firon M, Shaharabany M, Altstock RT et al. Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammmary cells. Oncogene 2000 19 2386 2397.
38. Belfiore A, Gangemi P, Costantino A et al. Negative/low expression of the Met/hepatocyte growth factor identifies papillary thyroid carcinomas with high risk of distant metastases. J. Clin. Endocrinol. Metab. 1997 82 2322 2328.
39. Shibamoto S, Hayakawa M, Takeuchi K et al. Tyrosine phosphorylation of beta-catenin and plakoglobin enhanced by hepatocyte growth factor and epidermal growth factor in human carcinoma cells. Cell Adhes. Commun. 1994 1 295 305.
40. Rahimi N, Tremblay E, McAdam L, Park M, Schwall R, Elliott B. Identification of a hepatocyte growth factor autocrine loop in a murine mammary carcinoma. Cell Growth Differ. 1995 7 263 270.
41. Zarnegar R, DeFrances MC. Expression of HGF-SF in normal and malignant human tissues. EXS 1993 65 181 199.
42. Zhang YW, Su Y, Lanning N et al. Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 2005 24 101 106.
43. Naldini L, Tamagogne L, Vigna E et al. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J. 1992 11 4825 4833.
44. Edakuni G, Sasatomi E, Satoh T, Tokunaga O, Miyazaki K. Expression of hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol. Int. 2001 51 172 178.